This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Women's Health  • Menopause  • Alert me on articles by topic

Kristen Suthers, PhD, MPH

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In the article by Tamimi and colleagues,¹ published in the July 24th issue of the ARCHIVES, the authors state, "To date, the only orally active testosterone preparation in the United States approved by the FDA [Food and Drug Administration] for the indication of menopausal symptoms is a fixed combination of methyltestosterone and esterified estradiol."^{1(p1483-1484)} The FDA has never approved Estratest (the combination product of methyltestosterone and esterified estradiol; Solvay Pharmaceuticals, Brussels, Belgium), for any indication, even its labeled indications. Solvay Pharmaceuticals states on the package insert for Estratest, "This product has not obtained FDA pre-market approval applicable for new drugs."² In 1981, Solvay Pharmaceuticals submitted an Abbreviated New Drug Application for Estratest; however, this application is still pending with the FDA—25 years later. Estratest has never been FDA approved.

Furthermore, in a notice published in the Federal Register on April 14, 2003, the FDA . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLE

Combined Estrogen and Testosterone Use and Risk of Breast Cancer in Postmenopausal Women
Rulla M. Tamimi, Susan E. Hankinson, Wendy Y. Chen, Bernard Rosner, and Graham A. Colditz
Arch Intern Med. 2006;166(14):1483-1489.
ABSTRACT | FULL TEXT